WuXi XDC Cayman Inc (2268.HK) Q4 2024 Earnings Report

WuXi XDC Cayman Inc delivered a standout Q4 2024 performance, highlighted by a 322.36% YoY revenue surge to CNY 2.388 billion and a strong bottom-line with net income of CNY 581.39 million. Gross margin stood at 29.51% and EBITDA reached CNY 587.07 million, translating to an EBITDA margin of 24.59% and an operating margin of 22.10%. EPS stood at CNY 0.48 (GAAP) with diluted EPS of CNY 0.44. The quarterly results reflect meaningful scale-up in contract development and manufacturing activities, particularly in antibody drug conjugates and related bioconjugates, supported by robust cash generation from operations (CNY 941.88 million). However, the period also featured substantial working capital consumption, with a negative change in working capital of CNY 989.92 million driven primarily by a sharp rise in accounts receivable, resulting in negative near-term free cash flow (FCF) of around CNY 41.45 million despite a healthy operating cash flow of CNY 941.88 million. The balance sheet remains solid, with total assets of CNY 9.12 billion and a net cash position (net debt) of approximately CNY -1.43 billion, underpinned by sizable cash and short-term investments (about CNY 3.97 billion). Absent explicit forward guidance, the quarter underscores the company’s ability to monetize scale while signaling near-term working capital normalization as a key monitorable risk. Going forward, growth remains tied to CDMO capacity expansion, conjugate program wins, and the broader WuXi Biologics ecosystem, with liquidity and low leverage providing optionality for capex and potential strategic collaborations.